Search
ADC Therapeutics SA
ADCTAdd to Watchlist
1.190USD
+0.065+5.70%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
151.33MMarket Cap
LossP/E TTM
More Details of ADC Therapeutics SA Company
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
ADC Therapeutics SA Info
Ticker SymbolADCT
Company nameADC Therapeutics SA
IPO dateMay 15, 2020
CEOMallik (Ameet)
Number of employees263
Security typeOrdinary Share
Fiscal year-endMay 15
AddressBiopole
CityEPALINGES
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountrySwitzerland
Postal code1066
Phone41216530200
Websitehttps://adctherapeutics.com/
Ticker SymbolADCT
IPO dateMay 15, 2020
CEOMallik (Ameet)
Company Executives of ADC Therapeutics SA
Name
Name/Position
Position
Shareholding
Change
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
2.35M
+10.02%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.61M
+1.85%
Mr. Mohamed Zaki, M.D., Ph.D.
Mr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
943.88K
+8.69%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
695.69K
+14.14%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
581.57K
+1.47%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Vice Chairman of the Board, Lead Independent Director
Non-Executive Vice Chairman of the Board, Lead Independent Director
222.99K
+19.21%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Independent Director
Non-Executive Independent Director
177.38K
+23.91%
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
131.80K
+24.58%
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Non-Executive Independent Director
Non-Executive Independent Director
95.41K
+33.96%
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Director
Director
72.40K
+44.75%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
2.35M
+10.02%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.61M
+1.85%
Mr. Mohamed Zaki, M.D., Ph.D.
Mr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
943.88K
+8.69%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
695.69K
+14.14%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
581.57K
+1.47%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Vice Chairman of the Board, Lead Independent Director
Non-Executive Vice Chairman of the Board, Lead Independent Director
222.99K
+19.21%
FAQs
Who are the top five shareholders of ADC Therapeutics SA?
The top five shareholders of ADC Therapeutics SA are: Mr. Ameet Mallik
How many institutions hold shares of ADC Therapeutics SA (ADCT)?
As of 2026Q1, 205 institutions hold shares of ADC Therapeutics SA, with a combined market value of approximately 87.78M, accounting for 69.09% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1768527.00.
What is the biggest source of revenue for ADC Therapeutics SA?
In 2026Q1, the Product business generated the highest revenue for ADC Therapeutics SA, amounting to 73.55M and accounting for 90.41% of total revenue.